"We look forward to the opportunity to introduce this evidence again through the legal process and in discussions ... was based on a thorough review of Novo Nordisk's stable and growing supply ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Moreover, Novo Nordisk also claims that it is difficult to manufacture liraglutide and "even small changes in the manufacturing process of ... made a similar case for semaglutide in a petition ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world lose weight. The molecule is semaglutide, and it's sold under the name ...

Novo Nordisk (NVO ... through the legal process and in discussions with the FDA. Compounders and telehealth providers have continued their offerings for both Novo's semaglutide and Eli Lilly's ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Without effective interventions, the global burden of obesity and its complications will continue to rise,” said Stephen Gough, senior vice president and head of Chief Medical Office at Novo Nordisk. ...